Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Beats Expectations By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK) posted its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38, Zacks reports. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $9.00 on Tuesday. The firm’s 50-day simple moving average is $9.53 and its two-hundred day simple moving average is $11.58. Stoke Therapeutics has a fifty-two week low of $5.60 and a fifty-two week high of $17.58. The stock has a market cap of $476.70 million, a PE ratio of -4.29 and a beta of 0.99.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on STOK shares. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. HC Wainwright lifted their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.